<DOC>
	<DOCNO>NCT00953056</DOCNO>
	<brief_summary>This study ass safety tolerability RotaTeq™ ( V260 ) healthy Chinese population . Approximately 144 participant enrol equally stratify three age cohort , Cohort I age 19-47 year , Cohort II age 2-6 year , Cohort III age 6-12 week . Randomization ratio 1:1 cohort . The study conduct sequentially , participant Cohort I Cohort II receive 1 dose , participant Cohort III receive 3 dos RotaTeq™/placebo . The primary investigator Ethics Review Committee review blind safety data make decision base best clinical judgment move study forward cohorts . Duration entire study approximately 6-9 month .</brief_summary>
	<brief_title>A Study V260 Healthy Chinese Adults , Children Infants ( V260-028 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult age 19 47 year Cohort I Healthy child age 2 6 year Cohort II Healthy infant age 6 12 week Cohort III Negative pregnancy test females Cohort I Signed Informed Consent Forms ( ICFs ) Participants Cohorts I II receive vaccine 14 day anticipate study vaccine Participants Cohort III receive nonconcomitant live vaccine 14 day study vaccine Prior administration rotavirus vaccine Elevated temperature , axillary temperature ≥37.1 Degrees C 24 hour study vaccine Prior active gastrointestinal illness , immunodeficiency Any condition may interfere evaluation study objective make participation study unsafe participant</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>